Amalgamated Bank Sells 405 Shares of STERIS plc (NYSE:STE)

Amalgamated Bank trimmed its holdings in shares of STERIS plc (NYSE:STE) by 2.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,059 shares of the medical equipment provider’s stock after selling 405 shares during the period. Amalgamated Bank’s holdings in STERIS were worth $4,404,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. First Personal Financial Services bought a new stake in STERIS during the first quarter valued at about $25,000. J.Safra Asset Management Corp grew its position in shares of STERIS by 77.9% in the 1st quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 53 shares during the last quarter. Quent Capital LLC raised its stake in shares of STERIS by 112.7% during the 1st quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 71 shares in the last quarter. Headlands Technologies LLC purchased a new stake in STERIS during the first quarter valued at approximately $36,000. Finally, Pingora Partners LLC acquired a new stake in STERIS in the fourth quarter valued at approximately $37,000. Hedge funds and other institutional investors own 94.69% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. KeyCorp raised their price target on STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a report on Tuesday, September 3rd. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a report on Thursday, August 8th. StockNews.com raised STERIS from a “hold” rating to a “buy” rating in a report on Tuesday, August 13th. Stephens reissued an “overweight” rating and issued a $260.00 price target on shares of STERIS in a report on Wednesday, August 7th. Finally, JMP Securities reissued a “market outperform” rating and issued a $265.00 price target on shares of STERIS in a report on Wednesday, August 7th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $246.00.

Insider Activity at STERIS

In related news, Director Christopher S. Holland sold 473 shares of STERIS stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $239.68, for a total transaction of $113,368.64. Following the completion of the transaction, the director now directly owns 582 shares in the company, valued at $139,493.76. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, Director Christopher S. Holland sold 473 shares of STERIS stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $239.68, for a total transaction of $113,368.64. Following the completion of the transaction, the director now directly owns 582 shares in the company, valued at $139,493.76. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Michael J. Tokich sold 23,332 shares of STERIS stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total value of $5,763,004.00. Following the transaction, the chief financial officer now owns 42,930 shares of the company’s stock, valued at $10,603,710. The disclosure for this sale can be found here. 1.14% of the stock is owned by company insiders.

STERIS Trading Down 1.0 %

STERIS stock opened at $236.98 on Friday. The company has a quick ratio of 1.49, a current ratio of 2.33 and a debt-to-equity ratio of 0.35. STERIS plc has a 52 week low of $195.47 and a 52 week high of $248.24. The company has a market capitalization of $23.43 billion, a price-to-earnings ratio of 62.04 and a beta of 0.83. The stock has a 50-day moving average price of $236.26 and a 200 day moving average price of $225.53.

STERIS (NYSE:STE) last released its earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 EPS for the quarter, topping analysts’ consensus estimates of $1.98 by $0.16. STERIS had a return on equity of 13.85% and a net margin of 7.36%. The firm had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.27 billion. During the same quarter in the previous year, the company posted $2.00 earnings per share. The company’s revenue was down .4% compared to the same quarter last year. Sell-side analysts anticipate that STERIS plc will post 9.05 EPS for the current year.

STERIS Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 20th. Investors of record on Thursday, September 5th were given a dividend of $0.57 per share. This is a boost from STERIS’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a yield of 0.96%. The ex-dividend date was Thursday, September 5th. STERIS’s dividend payout ratio (DPR) is currently 59.69%.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.